Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 16, 2022 | clinicaltrials |
| NCT03792958 | Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 19 | AnewPharmaINDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT04996771 |
| Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer |
| unknown |
| Phase 1 / Phase 2 |
| 88 |
| Sun Yat-sen UniversityOTHER |
| 1 |
| Nov 14, 2022 |
| clinicaltrials |
| NCT05461287 | Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 290 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 10, 2022 | clinicaltrials |
| NCT05559008 | A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | unknown | Phase 1 / Phase 2 | 116 | Ruijin HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT03774979 | SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors | unknown | Phase 1 | 193 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05608785 | Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes | unknown | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 0 | Nov 8, 2022 | clinicaltrials |
| NCT05609019 | A Study Evaluating SYHX2005 in the Treatment of Patients With Advanced Solid Tumors | unknown | Phase 1 | 139 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT00100256 | Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 60 | Andarix PharmaceuticalsINDUSTRY | 1 | Nov 7, 2022 | clinicaltrials |
| NCT03491631 | Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors | unknown | Phase 1 | 23 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 4, 2022 | clinicaltrials |
| NCT03855371 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS(PANDA-T0) | unknown | Phase 1 | 5 | Ruijin HospitalOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT00986661 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | unknown | Phase 1 | 78 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT03540017 | HIPEC After Initial CRS in Patients Who Have Received NACT | unknown | Phase 1 | 15 | Northwell HealthOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05602792 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 233 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05603039 | A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 80 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02098512 | Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients | unknown | Phase 1 / Phase 2 | 20 | New York Medical CollegeOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05596266 | CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | Xuanwu Hospital, BeijingOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05497310 | Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL | unknown | Phase 1 / Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05135858 | Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma(METHOGLU) | unknown | Phase 1 | 18 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT03750071 | VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | unknown | Phase 1 / Phase 2 | 30 | Vaximm GmbHINDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05588206 | Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 21 | First People's Hospital of HangzhouOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05587088 | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)(PA001) | unknown | Phase 1 / Phase 2 | 82 | Hospital Universitario San IgnacioOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05198752 | A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Stemirna TherapeuticsINDUSTRY | 2 | Oct 17, 2022 | clinicaltrials |
| NCT04255576 | Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone | unknown | Phase 1 / Phase 2 | 139 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05027204 | A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) | unknown | Phase 1 / Phase 2 | 94 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05577611 | An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | unknown | Phase 1 | 57 | Zhongnan HospitalOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT03825367 | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 13 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04118868 | Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma. | unknown | Phase 1 | 10 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04708210 | Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors | unknown | Phase 1 | 256 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05095441 | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | unknown | Phase 1 | 51 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05569057 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma | unknown | Phase 1 | 100 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 7, 2022 | clinicaltrials |
| NCT05569434 | 68Ga-P16-093 PET/CT Imaging in Glioma Patients | unknown | Phase 1 / Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT01946373 | T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma | unknown | Phase 1 | 20 | Karolinska University HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT04765462 | Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05522309 | FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors(FLIGHT) | unknown | Phase 1 | 37 | Etern BioPharma (Shanghai) Co., LtdINDUSTRY | 1 | Oct 4, 2022 | clinicaltrials |
| NCT03864211 | Thermal Ablation Followed by Immunotherapy for HCC | unknown | Phase 1 / Phase 2 | 145 | Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05557903 | Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL | unknown | Phase 1 | 71 | Lanzhou Institute of Biological Products Co., LtdINDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT01197625 | Vaccine Therapy in Curative Resected Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05150457 | Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 48 | Binacea Pharma, Inc.INDUSTRY | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05457517 | A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 49 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04684472 | Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies | unknown | Phase 1 | 18 | Liqun ZouOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT05552807 | SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | unknown | Phase 1 | 120 | Sinocelltech Ltd.INDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT05549973 | Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 | 32 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 100 | Wellmarker BioINDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT05541445 | Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC | unknown | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT04688853 | A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients | unknown | Phase 1 | 26 | Gadeta B.V.INDUSTRY | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05528887 | Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies | unknown | Phase 1 | 10 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Sep 6, 2022 | clinicaltrials |
| NCT03634982 | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors | unknown | Phase 1 | 133 | Revolution Medicines, Inc.INDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05524194 | 6MW3511 in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 272 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 0 | Sep 1, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Nov 16, 2022source: clinicaltrials